MiMedx Group, Inc. filed a current report on Form 8-K on October 28, 2026, announcing its results for the second quarter of 2026 and disclosing plans for an earnings conference call and updated investor presentation on the same date.

Key Highlights

  • Earnings release: MiMedx issued a press release on October 28, 2026, announcing its results for the second quarter of 2026, attached as Exhibit 99.1.
  • Conference call: The company disclosed plans to host an earnings call and webcast on October 28, 2026, at 4:30 PM Eastern Daylight Time, to discuss financial and operating results for the third quarter of 2026.
  • Earnings call presentation: A slide presentation for use during the earnings call was attached as Exhibit 99.2.
  • Updated investor presentation: The company updated its investor presentation on October 28, 2026, furnished as Exhibit 99.3.
  • Signed by CFO: The filing was signed by Doug Rice, Chief Financial Officer of MiMedx Group, Inc.
  • Rule 425 disclosure: The filing is checked as written communications pursuant to Rule 425 under the Securities Act.

MiMedx Discloses Q2 2026 Results and Q3 Earnings Call Details

MiMedx Group, Inc. (NASDAQ:MDXG), headquartered in Marietta, Georgia, filed a current report on October 28, 2026, under Item 2.02, "Results of Operations and Financial Condition," disclosing that it had issued an earnings press release announcing its second quarter of 2026 results. The press release is attached as Exhibit 99.1 and incorporated by reference into the filing. According to the filing, the information furnished under Item 2.02 "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

Under Item 7.01, Regulation FD, the company disclosed its intention to host a conference call and webcast on October 28, 2026, at 4:30 PM Eastern Daylight Time, to discuss financial and operating results specifically for the third quarter of 2026. A slide presentation to accompany the earnings call was furnished as Exhibit 99.2. Separately, an updated investor presentation was also furnished on October 28, 2026, as Exhibit 99.3.

The filing contains forward-looking statements relating to, among other items, future sales growth, 2026 and longer-term financial goals, expectations regarding the placental tissue market, Medicare reimbursement expectations, and performance in different care settings. The company cautioned that "actual results may differ materially from those set forth in the forward-looking statements" and noted additional risks are described in its most recent annual and quarterly reports filed with the SEC. The filing was signed by Doug Rice, Chief Financial Officer, and references a signature date of July 29, 2026.

What Was Disclosed

MiMedx filed an 8-K on October 28, 2026, furnishing its Q2 2026 earnings press release, a Q3 2026 earnings call slide presentation, and an updated investor presentation, along with forward-looking statement cautions.